Get the Stockscreener App
4.88
8.69%
0.39
Nyxoah Sa stock is traded at $4.88, with a volume of 59,012.
It is up +8.69% in the last 24 hours and down -2.59% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$4.49
Open:
$4.62
24h Volume:
59,012
Relative Volume:
1.32
Market Cap:
$209.97M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-2.9061
EPS:
-1.6792
Net Cash Flow:
$-60.34M
1W Performance:
+4.50%
1M Performance:
-2.59%
6M Performance:
-25.72%
1Y Performance:
-53.44%
1-Day Range:
$4.56
$4.95
1-Week Range:
$4.1001
$4.95
52-Week Range:
$4.1001
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
4.88 | 193.19M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
500.76 | 175.20B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
182.68 | 50.46B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
82.29 | 39.65B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
47.71 | 38.41B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
258.91 | 37.27B | 5.40B | 1.49B | 1.78B | 10.12 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Nyxoah Announces the Signature of a Memorandum of Understanding with Sheikh Shakhbout Medical City Hospital to Improve OSA Therapy Management and Accelerate Access to Genio in the Middle East - Bitget
Nyxoah Announces the Signature of a Memorandum of - GlobeNewswire
Nyxoah SA (NASDAQ:NYXH) Short Interest Up 29.0% in January - Defense World
(NYXH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Contrasting Hinge Health (NYSE:HNGE) and Nyxoah (NASDAQ:NYXH) - Defense World
Is Nyxoah SA stock undervalued right nowJuly 2025 Highlights & Weekly Stock Breakout Alerts - mfd.ru
Nyxoah SA (NYXH) Stock Analysis: A Healthcare Innovator with a Promising 138.98% Upside Potential - DirectorsTalk Interviews
Returns Recap: Will Nyxoah SA benefit from AI trendsWeekly Stock Recap & Community Supported Trade Ideas - baoquankhu1.vn
Is Nyxoah SA stock overvalued or fairly pricedJuly 2025 Update & Fast Gain Swing Trade Alerts - mfd.ru
Can Nyxoah SA expand into new marketsTrade Analysis Summary & Daily Profit Maximizing Trade Tips - mfd.ru
What is the long term forecast for Nyxoah SA stockJuly 2025 Sector Moves & High Accuracy Trade Signal Alerts - mfd.ru
Nyxoah's Revenue On The Rise- Will The Stock Wake From Its Slumber? - RTTNews
Guidance Update: Is now the right time to enter Nyxoah SABond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
Price-Driven Insight from (NYXH) for Rule-Based Strategy - Stock Traders Daily
Nyxoah SA (NYXH) Stock Analysis: A 137% Potential Upside In The Healthcare Sector - DirectorsTalk Interviews
Aug PreEarnings: Can Nyxoah SA sustain its profitabilityBear Alert & Expert Approved Trade Ideas - baoquankhu1.vn
Price Action: Should I hold or sell Nyxoah SA now2025 Institutional Moves & AI Driven Stock Movement Reports - baoquankhu1.vn
Ideas Watch: Is now the right time to enter Nyxoah SAQuarterly Trade Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Will Nyxoah SA benefit from rising consumer demandWeekly Stock Report & Smart Money Movement Tracker - baoquankhu1.vn
Nyxoah (NASDAQ:NYXH) Shares Down 0.4% – Time to Sell? - Defense World
Nyxoah (NASDAQ:NYXH) Shares Down 0.4%Time to Sell? - MarketBeat
Nyxoah Expands Belgian Manufacturing Hub to Support Global Growth in OSA Therapy - The Globe and Mail
Risk Hedge: Is Nyxoah SA stock a good dividend stockTrade Ideas & Long-Term Growth Plans - mfd.ru
Can Nyxoah SA sustain its profitabilityJuly 2025 Big Picture & AI Powered Buy and Sell Recommendations - mfd.ru
Volume Report: Can Nyxoah SA ride the EV waveQuarterly Portfolio Review & Weekly High Return Forecasts - baoquankhu1.vn
Nyxoah Expands Belgian Manufacturing Capacity to Support Global Growth - Sleep Review
Nyxoah SA (NYXH) Investor Outlook: Exploring a 137.85% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Nyxoah invests in further expanding its Belgian manufacturing capacity to support its worldwide growth - marketscreener.com
Nyxoah says co invests expanding its Belgian manufacturing capacity - marketscreener.com
Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth - GlobeNewswire
Does Nyxoah SA have pricing power2025 Risk Factors & Growth Focused Stock Reports - bollywoodhelpline.com
Aug Sectors: Is Flanigans Enterprises Inc stock a falling knife or bargain buy2025 Fundamental Recap & Intraday High Probability Alerts - baoquankhu1.vn
(NYXH) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NYXH: Rapid U.S. launch and strong clinical results position Genio for significant market growth - TradingView
NYXH: Genio's innovative sleep apnea device drives rapid U.S. adoption and strong early sales - TradingView — Track All Markets
Oppenheimer Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
Nyxoah’s First Full U.S. Sales Quarter Fuels Triple-Digit Revenue Growth in 2025 - The Globe and Mail
Nyxoah (NASDAQ: NYXH) reports preliminary 2025 results and Q1 2026 view - Stock Titan
Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target By Investing.com - Investing.com South Africa
Stifel Maintains Nyxoah SA(NYXH.US) With Buy Rating, Maintains Target Price $12 - 富途资讯
Stifel reiterates Buy rating on Nyxoah stock, maintains $12 price target - Investing.com Australia
Is Nyxoah SA stock a safe investment in uncertain markets2025 Growth vs Value & Verified Swing Trading Watchlist - Bộ Nội Vụ
Belgium-based Nyxoah’s net revenue expected to increase 348% in Q4 2025 - Medical Buyer
Nyxoah Shares Surge On Strong Q4 Preliminary Revenue - Nasdaq
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 - The Manila Times
News - FinancialContent
Publication relating to transparency notification - GlobeNewswire
Nyxoah SA's (EBR:NYXH) market cap rose €19m last week; retail investors who hold 44% profited and so did insiders - simplywall.st
Aug Opening: Is Nyxoah SA stock a contrarian buyJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - Bộ Nội Vụ
Is Nyxoah SA stock a good choice for value investorsSeasonal Picks & what to check before ordering - Улправда
Is Nyxoah SA stock a contrarian buyMarket Risk Summary & Free Fast Gain Swing Trade Alerts - Улправда
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):